BNP Paribas Financial Markets’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $637K | Sell |
75,152
-180,769
| -71% | -$1.72M | ﹤0.01% | 3458 |
|
|
2025
Q4 | $3.11M | Buy |
255,921
+226,426
| +768% | +$2.75M | ﹤0.01% | 2341 |
|
|
2025
Q3 | $345K | Sell |
29,495
-179,035
| -86% | -$2.14M | ﹤0.01% | 3750 |
|
|
2025
Q2 | $1.94M | Buy |
208,530
+154,047
| +283% | +$1.21M | ﹤0.01% | 2495 |
|
|
2025
Q1 | $399K | Sell |
54,483
-20,917
| -28% | -$161K | ﹤0.01% | 3312 |
|
|
2024
Q4 | $644K | Buy |
75,400
+39,599
| +111% | +$386K | ﹤0.01% | 3114 |
|
|
2024
Q3 | $311K | Sell |
35,801
-19,513
| -35% | -$161K | ﹤0.01% | 3057 |
|
|
2024
Q2 | $378K | Sell |
55,314
-129,994
| -70% | -$802K | ﹤0.01% | 2806 |
|
|
2024
Q1 | $1.69M | Buy |
185,308
+146,138
| +373% | +$1.04M | ﹤0.01% | 2164 |
|
|
2023
Q4 | $175K | Sell |
39,170
-31,689
| -45% | -$93.7K | ﹤0.01% | 3264 |
|
|
2023
Q3 | $222K | Buy |
70,859
+50,685
| +251% | +$207K | ﹤0.01% | 3055 |
|
|
2023
Q2 | $104K | Sell |
20,174
-28,057
| -58% | -$167K | ﹤0.01% | 3243 |
|
|
2023
Q1 | $254K | Buy |
48,231
+32,102
| +199% | +$152K | ﹤0.01% | 3054 |
|
|
2022
Q4 | $45.3K | Sell |
16,129
-60,664
| -79% | -$201K | ﹤0.01% | 3439 |
|
|
2022
Q3 | $319K | Sell |
76,793
-29,444
| -28% | -$148K | ﹤0.01% | 3263 |
|
|
2022
Q2 | $427K | Sell |
106,237
-35,734
| -25% | -$135K | ﹤0.01% | 2741 |
|
|
2022
Q1 | $703K | Sell |
141,971
-37,570
| -21% | -$208K | ﹤0.01% | 2551 |
|
|
2021
Q4 | $1.25M | Buy |
179,541
+165,981
| +1,224% | +$1.29M | ﹤0.01% | 2434 |
|
|
2021
Q3 | $136K | Buy |
13,560
+10,714
| +376% | +$120K | ﹤0.01% | 3171 |
|
|
2021
Q2 | $40.4K | Sell |
2,846
-6,717
| -70% | -$102K | ﹤0.01% | 3343 |
|
|
2021
Q1 | $157K | Sell |
9,563
-3,806
| -28% | -$73.3K | ﹤0.01% | 3151 |
|
|
2020
Q4 | $277K | Sell |
13,369
-908
| -6% | -$13.5K | ﹤0.01% | 2732 |
|
|
2020
Q3 | $109K | Buy |
14,277
+12,151
| +572% | +$101K | ﹤0.01% | 3075 |
|
|
2020
Q2 | $17.7K | Sell |
2,126
-11,023
| -84% | -$73.1K | ﹤0.01% | 3452 |
|
|
2020
Q1 | $65.1K | Buy |
13,149
+6,803
| +107% | +$33.6K | ﹤0.01% | 3425 |
|
|
2019
Q4 | $25.1K | Buy |
6,346
+411
| +7% | +$1.43K | ﹤0.01% | 3937 |
|
|
2019
Q3 | $18K | Buy |
5,935
+1,862
| +46% | +$8.32K | ﹤0.01% | 3988 |
|
|
2019
Q2 | $17.9K | Sell |
4,073
-3,431
| -46% | -$12.7K | ﹤0.01% | 3935 |
|
|
2019
Q1 | $29.8K | Buy |
+7,504
| New | +$30.2K | ﹤0.01% | 3775 |
|
|
2018
Q4 | – | Sell |
-1,074
| Closed | -$7.39K | – | 4393 |
|
|
2018
Q3 | $7.39K | Hold |
1,074
| – | – | ﹤0.01% | 3888 |
|
|
2018
Q2 | $7.25K | Sell |
1,074
-5,333
| -83% | -$36.6K | ﹤0.01% | 3931 |
|
|
2018
Q1 | $41.7K | Buy |
6,407
+1,105
| +21% | +$6.22K | ﹤0.01% | 3651 |
|
|
2017
Q4 | $23.6K | Buy |
5,302
+2,855
| +117% | +$14.6K | ﹤0.01% | 3933 |
|
|
2017
Q3 | $15.1K | Sell |
2,447
-495
| -17% | -$3.19K | ﹤0.01% | 3737 |
|
|
2017
Q2 | $27.3K | Buy |
2,942
+2,861
| +3,532% | +$27.7K | ﹤0.01% | 3485 |
|
|
2017
Q1 | $752 | Sell |
81
-962
| -92% | -$8.01K | ﹤0.01% | 3759 |
|
|
2016
Q4 | $8.73K | Sell |
1,043
-168
| -14% | -$1.3K | ﹤0.01% | 3510 |
|
|
2016
Q3 | $8.32K | Buy |
1,211
+509
| +73% | +$3.1K | ﹤0.01% | 3260 |
|
|
2016
Q2 | $3.48K | Buy |
+702
| New | +$6.96K | ﹤0.01% | 3385 |
|
|
2016
Q1 | – | Sell |
-2,766
| Closed | -$25.9K | – | 2953 |
|
|
2015
Q4 | $25.9K | Sell |
2,766
-409
| -13% | -$4.42K | ﹤0.01% | 3200 |
|
|
2015
Q3 | $44.6K | Buy |
3,175
+2,091
| +193% | +$42K | ﹤0.01% | 2942 |
|
|
2015
Q2 | $22.8K | Buy |
1,084
+953
| +727% | +$23.6K | ﹤0.01% | 2961 |
|
|
2015
Q1 | $5.5K | Buy |
+131
| New | +$4.31K | ﹤0.01% | 3101 |
|
Other funds holding OCUL
DTC
ACA
SR
VA
VCM
BNP Paribas Financial Markets's OCUL Position: Q1 2026 in Review
BNP Paribas Financial Markets reduced its Ocular Therapeutix (OCUL) stake by 71% in Q1 2026, selling an estimated $1.72M and leaving 75,152 shares worth $637K. The position accounts for ﹤0.01% of the portfolio, ranked #3458.
BNP Paribas Financial Markets first reported a position in OCUL in Q1 2015 and has held it in 43 quarters since. The position peaked at $3.11M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.
- BNP Paribas Financial Markets held 75,152 shares of Ocular Therapeutix worth $637K as of Q1 2026.
- BNP Paribas Financial Markets sold 180,769 Ocular Therapeutix shares in Q1 2026, an estimated $1.72M.
- Ocular Therapeutix made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3458 holding.
- BNP Paribas Financial Markets first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 43 quarters since.
- BNP Paribas Financial Markets's Ocular Therapeutix position peaked at $3.11M in Q4 2025.
- 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.